Zacks: Analysts Set $27.00 Target Price for Collegium Pharmaceutical Inc (NASDAQ:COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) has been given a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have given a strong buy recommendation to the company.

Brokers have set a one year consensus price target of $27.00 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Collegium Pharmaceutical an industry rank of 61 out of 265 based on the ratings given to related companies.

Collegium Pharmaceutical (NASDAQ:COLL) opened at 27.50 on Monday. Collegium Pharmaceutical has a one year low of $11.92 and a one year high of $30.58. The firm’s market capitalization is $568.92 million. The stock has a 50 day moving average price of $22.31 and a 200 day moving average price of $19.47.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, November 12th. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.16. On average, equities analysts predict that Collegium Pharmaceutical will post ($1.87) EPS for the current fiscal year.

COLL has been the subject of several research reports. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, November 30th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, September 14th.

12 Month Chart for NASDAQ:COLL

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (NASDAQ:COLL) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Boeing Profit Drops on Lag in Commercial Deliveries
Boeing Profit Drops on Lag in Commercial Deliveries


Leave a Reply

 
© 2006-2017 The Vista Voice. Subscribe